Ashley Ghiaseddin

Ashley Ghiaseddin, M.D.

Clinical Associate Professor

Department: MD-NEUROLOGICAL SURGERY
Business Phone: (352) 273-9000

About Ashley Ghiaseddin

My name is Ashley Ghiaseddin, MD, and I’m a neuro-oncologist and chief of the division of neuro-oncology in UF’s Department of Neurosurgery. I specialize in brain cancer treatment, using targeted methods including chemotherapy, immunotherapy and precision medicine for patients with malignant brain tumors, such as glioblastoma.

I graduated with a bachelor’s degree in science and business from the University of Notre Dame and completed my medical degree at the University of Toledo. I went on to complete my residency at Indiana University and a neuro-oncology fellowship at Duke University.

I am a member of the Preston A. Wells Jr. Center for Brain Tumor Therapy, where I collaborate with an interdisciplinary team of experts dedicated to delivering patient-centered care and discovering better treatments for brain tumors.

In addition to taking care of patients, I conduct research into novel immunotherapy approaches to treat brain cancer and improve outcomes for patients. I am also interested in population-based studies involving glioblastoma and identifying ways to improve quality of life for patients and caregivers.

I am a leader in the neuro-oncology section of the American Academy of Neurology, and I am a member of the Society for Neuro-Oncology and the American Society of Clinical Oncology.

As a neuro-oncologist, I remain active in clinical trials as well as in authoring manuscripts. I run large investigator-initiated trials, and am currently serving as PI for multiple studies.

Conditions that I focus on treating include glioblastoma, astrocytoma, oligodendroglioma, cns lymphoma, ependymoma, neurocytoma and meningioma.

In my free time, I enjoy spending time with my family, walking, traveling and exploring Florida.

Teaching Profile

Courses Taught
2018
BMS6812 Intro Clin Med 2

Board Certifications

  • Neurology
    American Board of Psychiatry and Neurology

Clinical Profile

Specialties
  • Neuro-Oncology
Areas of Interest
  • Brain Tumors
  • Glioblastoma multiforme
  • Meningioma
  • Metastatic Brain Tumor
  • Primary lymphoma of the brain

Publications

Academic Articles
2025
How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma?
Neuro-oncology practice. 12(Suppl 1):i19-i25 [DOI] 10.1093/nop/npae112. [PMID] 39776526.
2025
Opiate Use Patterns Following Surgery for High Grade Glioma
World Neurosurgery. 194 [DOI] 10.1016/j.wneu.2024.11.090.
2025
Predictive Power of the Fried Phenotype in Assessing Postoperative Outcomes in Patients Undergoing Craniotomy for Tumor Resection.
Neurosurgery. 96(2):463-470 [DOI] 10.1227/neu.0000000000003231. [PMID] 39471075.
2025
Safety and Efficacy of Ketorolac After Craniotomy for Tumor Resection
World Neurosurgery. 194 [DOI] 10.1016/j.wneu.2024.10.068.
2024
Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions.
Neuro-oncology advances. 6(1) [DOI] 10.1093/noajnl/vdae025. [PMID] 38486856.
2024
Developing a computable phenotype for glioblastoma.
Neuro-oncology. 26(6):1163-1170 [DOI] 10.1093/neuonc/noad249. [PMID] 38141226.
2024
Discontinuation of Antiseizure Medications in Patients With Brain Tumors.
Neurology. 102(4) [DOI] 10.1212/WNL.0000000000209163. [PMID] 38290092.
2024
Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients.
Cancer. 130(9):1577-1589 [DOI] 10.1002/cncr.35220. [PMID] 38288941.
2024
RNA aggregates harness the danger response for potent cancer immunotherapy.
Cell. 187(10):2521-2535.e21 [DOI] 10.1016/j.cell.2024.04.003. [PMID] 38697107.
2024
The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations.
World neurosurgery. 181:e133-e153 [DOI] 10.1016/j.wneu.2023.09.042. [PMID] 37739175.
2023
Clinical management of seizures in patients with meningiomas: Efficacy of surgical resection for seizure control and patient-tailored postoperative anti-epileptic drug management.
Neuro-oncology advances. 5(Suppl 1):i58-i66 [DOI] 10.1093/noajnl/vdac136. [PMID] 37287578.
2023
Duration of Prophylactic Levetiracetam After Surgery for Brain Tumor: A Prospective Randomized Trial.
Neurosurgery. 92(1):68-74 [DOI] 10.1227/neu.0000000000002164. [PMID] 36156532.
2023
In Reply to the Letter to the Editor Regarding “Histologic Findings at the Time of Repeat Resection Predicts Survival in Patients with Glioblastoma”.
World neurosurgery. 170 [DOI] 10.1016/j.wneu.2022.12.037. [PMID] 36782416.
2023
mRNA aggregates harness danger response for potent cancer immunotherapy.
medRxiv : the preprint server for health sciences. [DOI] 10.1101/2023.03.12.23287108. [PMID] 36993772.
2023
Patterns and predictors of anxiety and depression symptom trajectories in patients diagnosed with primary brain tumors.
Journal of neuro-oncology. 164(3):701-710 [DOI] 10.1007/s11060-023-04469-2. [PMID] 37804375.
2022
Glioma Immunotherapy: Advances and Challenges for Spinal Cord Gliomas.
Neurospine. 19(1):13-29 [DOI] 10.14245/ns.2143210.605. [PMID] 35130421.
2022
Histologic Findings at the Time of Repeat Resection Predicts Survival in Patients with Glioblastoma.
World neurosurgery. 168:e451-e459 [DOI] 10.1016/j.wneu.2022.09.128. [PMID] 36206964.
2022
The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival.
Journal of neuro-oncology. 159(2):479-484 [DOI] 10.1007/s11060-022-04083-8. [PMID] 35840786.
2021
Adult precision medicine: learning from the past to enhance the future.
Neuro-oncology advances. 3(1) [DOI] 10.1093/noajnl/vdaa145. [PMID] 33543142.
2021
In situ vaccination with laser interstitial thermal therapy augments immunotherapy in malignant gliomas.
Journal of neuro-oncology. 151(1):85-92 [DOI] 10.1007/s11060-020-03557-x. [PMID] 32757094.
2021
Inflammatory myofibroblastic tumor masquerading as an anterior choroidal artery fusiform aneurysm.
Surgical neurology international. 12 [DOI] 10.25259/SNI_113_2021. [PMID] 34221627.
2021
Intracranial myxoid mesenchymal neoplasms with EWSR1 gene rearrangement: report of 2 midline cases with one demonstrating durable response to MET inhibitor monotherapy.
Neuro-oncology advances. 3(1) [DOI] 10.1093/noajnl/vdab016. [PMID] 33738448.
2021
Role of Laser Interstitial Thermal Therapy in the Management of Primary and Metastatic Brain Tumors.
Current treatment options in oncology. 22(12) [DOI] 10.1007/s11864-021-00912-6. [PMID] 34687357.
2020
Introducing a Supportive Care Team for Advance Directive Education in a Neurological and Neurosurgical Patient Population.
Journal of patient experience. 7(6):1286-1293 [DOI] 10.1177/2374373520932449. [PMID] 33457577.
2020
Tumor Treating Fields in the Management of Patients with Malignant Gliomas.
Current treatment options in oncology. 21(9) [DOI] 10.1007/s11864-020-00773-5. [PMID] 32734509.
2018
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
The oncologist. 23(2):157-e21 [DOI] 10.1634/theoncologist.2017-0501. [PMID] 29133513.
2017
Eleven Month Progression-Free Survival on Vemurafenib Monotherapy in a Patient With Recurrent and Metastatic BRAF V600E-Mutated Glioblastoma WHO Grade 4.
JCO precision oncology. 1:1-5 [DOI] 10.1200/PO.17.00055. [PMID] 35172504.
2015
Use of bevacizumab in recurrent glioblastoma.
CNS oncology. 4(3):157-69 [DOI] 10.2217/cns.15.8. [PMID] 25906439.

Grants

Oct 2024 ACTIVE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune? (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune? Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58)
Role: Principal Investigator
Funding: NOVOCURE Ltd
Mar 2023 ACTIVE
Adoptive Cellular Therapy Targeting Recurrent/Progressive Oligodendroglioma
Role: Co-Investigator
Funding: OLIGO NATION
Aug 2022 – Mar 2023
Image analysis for ATTAC-II: A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-pulsed Dendritic Cells with Tetanus-Diphtheria Toxoid Vaccine in Patients with Newly-Diagnosed Glioblastoma
Role: Principal Investigator
Funding: IMAGE ANALYSIS GROUP
Sep 2021 – Jun 2022
Neosoma Brain Tumor Image Analysis and Workflow Software
Role: Co-Investigator
Funding: NEOSOMA
Feb 2021 ACTIVE
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Sep 2020 – Aug 2023
Clinical Development of CAR T Cell Therapy Targeting CD70 in Primary Glioblastoma
Role: Co-Investigator
Funding: US ARMY MED RES ACQUISITION
Jul 2019 – Jun 2024
OoR Matching Support for CTSI
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Mar 2019 – Mar 2024
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Feb 2018 ACTIVE
Phase 2, Single Arm, Historically Controlled Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune?) Plus Pembrolizumab in Patients with Newly Diagnosed Glioblastoma
Role: Principal Investigator
Funding: NOVOCURE Ltd
Jul 2016 – Jul 2019
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Role: Principal Investigator
Funding: ORBUS THERAPEUTICS INC
Nov 2015 ACTIVE
A PHASE I OPEN LABEL, RANDOMIZED, CONTROLLED PHASE II STUDY TESTING THE SAFETY, TOXICITIES, AND EFFICACY OF MK-3475…
Role: Principal Investigator
Funding: WASHINGTON UNIV SAINT LOUIS via MERCK AND COMPANY INC

Education

Fellowship – Neuro-oncology
2015 · Duke University
Residency – Neurology
2014 · Indiana University
Internship – Internal Medicine
2011 · Indiana University
Medical Degree
2010 · University of Toledo

Contact Details

Phones:
Business:
(352) 273-9000
Addresses:
Business Mailing:
PO BOX 100265
DEPARTMENT OF NEUROSURGERY
GAINESVILLE FL 326100265
Business Street:
PO Box 100265
GAINESVILLE FL 32610